Call freephone

03300 575 838

  • Recruiting Now​

Myasthenia Gravis

Myasthenia gravis (gMB) is a rare chronic condition that causes weakness if voluntary muscles including muscles in the face, throat and muscles connecting to a person’s bones. It is an autoimmune disease meaning the body’s defence system attacks healthy cells or proteins mistakenly.

4MCS are running a clinical trial to test a new medication versus a non-active substance (placebo) to see if it can improve symptoms of myasthenia gravis.

To enrol on a myasthenia gravis clinical trial or learn more about participating, please fill in the form below and we will be in touch. Alternatively, please call our team on 03300 575 838.

  • 18-75 years old
  • Male or female between ages 18-75 years old Diagnosis of Myasthenia gravis On a stable standard of care gMB treatment Other criteria with apply based on medical history
Register Interest

clinical trials

Frequently Asked Questions

We understand you may have questions about participating in our clinical trial. Here are answers to some of the most common questions we receive from potential participants. For more information, visit our full FAQs page or browse our Information Hub.

What does stable treatment mean?
Stable standard-of-care treatment means your current myasthenia gravis medications haven’t needed significant changes recently. This might include acetylcholinesterase inhibitors, immunosuppressants, or corticosteroids that help manage your autoimmune disease. Stability is crucial for clinical trial safety and scientific validity. When we test new treatments in double blind, controlled studies, we need a consistent baseline treatment to accurately measure the efficacy and safety of the study medication.
Our myasthenia gravis clinical trials involve regular visits where you’ll receive comprehensive assessments from our specialised team. You’ll receive either the new medication or a placebo – neither you nor researchers will know which during the double blind study period. We’ll monitor your progress using standardised measures like MG ADL scores to track improvements in daily activities. Regular safety monitoring includes checking for side effects and ensuring the treatment doesn’t cause any life-threatening complications.
Recent advances in treating myasthenia gravis are encouraging. New approaches targeting different aspects of this autoimmune disease include FcRn inhibitors, complement inhibitors, and emerging therapies like CAR T cell therapy (chimeric antigen receptor T cells). Some clinical trials in myasthenia gravis research have already led to new approved treatments, while other studies explore open-label trials of innovative approaches. The field has seen remarkable progress in understanding how to better target the immune system problems causing muscle weakness.
Cutting-edge approaches like CAR T cell therapy (chimeric antigen receptor T cell treatment) represent exciting developments for patients with generalised myasthenia gravis. These treatments modify your immune system cells to better fight the autoimmune disease. While our current clinical trial focuses on established approaches with proven efficacy and safety profiles, the broader field includes research into these advanced treatments for treating myasthenia gravis more effectively.

speak to an expert

03300 575 838

volunteer@4mcs.co.uk

Enquire to participate

Become A Participant